ACTRN12621000741886招募中未知
Single-Arm, Multicenter, Study to Evaluate Safety and Efficacy of an Ultra-Low Frequency Spinal Cord Stimulator in Subjects with Painful Diabetic Neuropathy
Presidio Medical AU Pty Ltd0 个研究点目标入组 10 人开始时间: 2021年6月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Have been diagnosed with lower extremity painful diabetic neuropathy for a minimum of 3 months
- •2.VAS greater than or equal to 50mm for the past week
- •3.Have stable neurological status
- •4.Eighteen (18) years of age or older
- •5.Literate, able to speak English and able to complete questionnaires independently
- •6.Willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol
- •7.Are currently receiving optimal medical management and considered medically stable as judged by investigator
- •8.Ability to independently change AA batteries and operate EPG.
- •9.Able to comply with study requirements and attend all scheduled visits
排除标准
- •1.Have a diagnosis of a lower limb mononeuropathy, have had a lower limb amputation, or have ulcers of the lower limbs
- •2.If female and sexually active, and the subject is not using a reliable form of birth control, is not surgically sterile or at least two years post-menopausal, the subject shall be excluded, as confirmed by the investigator
- •3.A Hemoglobin A1C (HgB A1C) level that is greater than (>) 9%
- •4.Body Mass Index (BMI) score that is > 40
- •5.Diagnosis of Fibromyalgia
- •6.VAS greater than or equal to 30mm in the legs or trunk that would make accurate assessment of change difficult, as determined by investigator.
- •7.Severe cognitive impairment as determined by investigator
- •8.Average total daily morphine equivalent dose (MED) of >100 mg
- •9.A psychological assessment will be performed at Baseline to exclude any diagnosis of active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance, intervention and/or ability to evaluate treatment outcome as assessed by a clinical psychologist or psychiatrist.
- •10.Spinal stenosis or other structural spinal abnormality observed on MRI (or CT scan) that would make lead placement unsafe or untowardly difficult as determined by investigator
- •11.Currently taking anticoagulants including Warfarin, Heparin, Low Molecular Weight Heparin, Factor Xa inhibitors, GPIIb/IIIa inhibitors, thienopyridine inhibitors, direct thrombin inhibitors, or any other anticoagulant that is a contraindication to epidural lead placement within 1 week of the Screening Visit
- •12.Current coagulopathy, thrombocytopenia or bleeding diathesis (confirmed by clinical history and, if clinically indicated, by coagulation screening)
- •13.Cardiac demand pacemaker, implanted defibrillator or another implanted electronic device
- •14.A systemic condition or disease not stabilized or judged by the investigator to be incompatible with participation in the study (e.g. current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction, etc.)
- •15.Known hypersensitivity to any of the procedural agents or materials in the study device that is inserted into the subject
- •16.Previous use of spinal cord stimulation or comparable therapy
- •17.A known need for an MRI or surgery between the screening visit through the end of the study.
- •18.Any experimental drug or device used within 30 days prior to the Screening Visit or during the course of the clinical trial
- •19.Subjects who are involved in ongoing or closed (within 30 days of the screening visit) litigation related to their pain condition
研究者
相似试验
已完成
不适用
Single-Arm, Multicenter Study to Evaluate Safety and Efficacy of Low Frequency Spinal Cord Stimulator in Subjects with Low Back and/or Leg Paiower back painLeg PainLower back painNeurological - Other neurological disordersMusculoskeletal - Other muscular and skeletal disordersACTRN12619001252101Presidio Medical AU, Pty Ltd20
已完成
2 期
Single arm, multicentre study of Carfilzomib in combination with Thalidomide and Dexamethasone (CaTD) in patients with relapsed and/or refractory multiple myeloma (RRMM).Multiple MyelomaACTRN12615000818538Australiasian Leukaemia and Lymphoma Group91
进行中（未招募）
1 期
CS12 adolescent studyEUCTR2011-002065-37-NOBayer HealthCare AG304
进行中（未招募）
不适用
CS12 adolescent studyContraceptionMedDRA version: 14.1Level: PTClassification code 10010808Term: ContraceptionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2011-002065-37-ATBayer HealthCare AG360
已完成
3 期
Multi-center, single-arm study to assess the safety, efficacy, discontinuation rate and pharmacokinetics of the low-dose levonorgestrel intrauterine contraceptive system (LCS12) in post-menarcheal female adolescents under 18 years of age for 1 year, and an optional 2-year extension phaseintrauterine anticonceptieintrauterine system as a contraceptiveprevention of pregnancyNL-OMON40073Bayer96